Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Average Target Price from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been given an average rating of “Buy” by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $9.50.

QNCX has been the topic of a number of recent research reports. Rodman & Renshaw began coverage on Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Quince Therapeutics in a research report on Thursday. Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd.

Hedge Funds Weigh In On Quince Therapeutics

An institutional investor recently raised its position in Quince Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the period. Geode Capital Management LLC owned 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Price Performance

NASDAQ QNCX opened at $1.95 on Thursday. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The stock has a 50-day moving average of $1.80 and a 200 day moving average of $1.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The company has a market capitalization of $85.80 million, a price-to-earnings ratio of -1.57 and a beta of 0.74.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.